Dr. Jessica Ailani and Dr. Kathleen Digre discuss the evolution of spontaneous intracranial hypotension (SIH) diagnosis and treatment over the past decade.

In part one of this two-part series, Dr. Dan Ackerman and Dr. Trey Bateman discuss current biomarkers for Alzheimer disease and how do you use them in clinic. 

Dr. Justin Abbatemarco discusses updates around MOGAD treatments. 

Show references:

https://jamanetwork.com/journals/jamaneurology/article-abstract/2822964 

https://jnnp.bmj.com/content/95/11/1054 

Dr. Justin Abbatemarco discusses autoimmune encephalitis with a focus on outcomes.

Show references:

https://www.neurology.org/doi/10.1212/WNL.0000000000210109 

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00463-5/abstract 

Dr. Halley Alexander discusses the Neurology Today article, “The AAN Updates Its Position Statement on Seizures, Driver Licensure, and Medical Reporting,” by Gina Shaw, available in the latest issue of Neurology Today or at neurologytoday.com. 

Show reference:

The AAN Updates Its Position Statement on Seizures, Driver Licensure, and Medical Reporting

Dr. Greg Cooper and Dr. Joseph Therriault discuss the use of plasma biomarkers in diagnosing Alzheimer disease.

Show reference:

https://doi.org/10.1038/s43587-024-00731-y 

Dr. Halley Alexander and Dr. Paula Marques discuss sex differences in genetically determined epilepsies.

Show reference: 

https://www.neurology.org/doi/10.1212/NXG.0000000000200233 

Dr. Justin Abbatemarco discusses updates around treatments in AQP4+ NMOSD. 

Show references:

https://pubmed.ncbi.nlm.nih.gov/38760098/

https://www.neurology.org/doi/10.1212/NXI.0000000000200071

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how to address questions related to BTK Inhibitors with patients.

Show reference:

https://www.nejm.org/doi/full/10.1056/NEJMoa2415985  

https://www.nejm.org/doi/full/10.1056/NEJMoa2415988  

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss the clinical trial data available in both the relapsing and progressive cohorts.

Show reference:

https://www.nejm.org/doi/full/10.1056/NEJMoa2415985 

https://www.nejm.org/doi/full/10.1056/NEJMoa2415988